

Electronic Acknowledgement Receipt

EFS ID:	3609137
Application Number:	10524316
International Application Number:	
Confirmation Number:	6458
Title of Invention:	Analgesic agent for newborn or fetal subjects
First Named Inventor/Applicant Name:	Nicholas Peter Franks
Customer Number:	27885
Filer:	Zeba Ali/Robert Hurley
Filer Authorized By:	Zeba Ali
Attorney Docket Number:	YOUZ 2 00109
Receipt Date:	14-JUL-2008
Filing Date:	09-FEB-2005
Time Stamp:	13:48:28
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 930
RAM confirmation Number	7608
Deposit Account	110600
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		2839-46401_Response-with-Exhibits.pdf	559144 531282430a404407e966cefab915f8ad31ee7322	yes	13
Multipart Description/PDF files in .zip description					
Document Description		Start		End	
Amendment Submitted/Entered with Filing of CPA/RCE		1		1	
Claims		2		4	
Applicant Arguments/Remarks Made in an Amendment		5		13	

Warnings:

Information:

2	Request for Continued Examination (RCE)	2839-46401_REQUEST-FO R-CONTINUED-EXAMINATI ON-RCE-TRANSMITTAL_sb 0030e_fill.pdf	779485 585fed68f171349ba1efef5074c2fb5a685 013bc3	no	3
---	---	---	---	----	---

Warnings:

Information:

3	Extension of Time	2839-46401_EOT.pdf	121891 0eb147a6e2d5c33d184ed053f32770619 3964d71f	no	1
---	-------------------	--------------------	---	----	---

Warnings:

Information:

4	Fee Worksheet (PTO-06)	fee-info.pdf	8334 de3ae7c74a3562428e5d587118395166 14f890a4	no	2
---	------------------------	--------------	--	----	---

Warnings:

Information:

Total Files Size (in bytes):			1468854
-------------------------------------	--	--	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.